

EXHIBIT C

EXHIBIT C

U.S. Application No. 09/509,283

Pending Claims Following Entry of Amendments Made Herein

71. (New) A monoclonal antibody that recognizes a human 8F4 polypeptide or a fragment thereof, wherein said 8F4 polypeptide:

- a) is an inducible T cell costimulatory molecule;
- b) occurs on two-signal-activated human T lymphocytes;
- c) exhibits a molecular weight of about 55 to 60 kilodaltons as determined by non-reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE); and
- d) is a dimer of two peptide chains exhibiting molecular weights of about 27 kilodaltons and 29 kilodaltons, as measured by reducing SDS-PAGE.

72. (New) The monoclonal antibody of Claim 71, wherein said monoclonal antibody recognizes the human 8F4 polypeptide of about 55 kilodaltons to 60 kilodaltons, as determined by non-reducing SDS-PAGE.

73. (New) The monoclonal antibody of Claim 71, wherein said monoclonal antibody recognizes the peptide chain of about 27 kilodaltons, as determined by reducing SDS-PAGE.

74. (New) The monoclonal antibody of Claim 71, wherein said monoclonal antibody recognizes the peptide chain of about 29 kilodaltons, as determined by reducing SDS-PAGE.

75. (New) The monoclonal antibody of Claim 71, wherein said monoclonal antibody recognizes a human 8F4 polypeptide present on activated human CD4⁺ T lymphocytes and activated human CD8⁺ T lymphocytes.

76. (New) The monoclonal antibody of Claim 71, wherein the monoclonal antibody inhibits a biological activity of the human 8F4 polypeptide.

77. (New) The monoclonal antibody of Claim 71, wherein the monoclonal antibody activates a biological activity of the human 8F4 polypeptide.

78. (New) A hybridoma that produces a monoclonal antibody that recognizes a human 8F4 polypeptide or a fragment thereof, wherein said 8F4 polypeptide:

- a) is an inducible T cell costimulatory molecule;
- b) occurs on two-signal-activated human T lymphocytes;
- c) exhibits a molecular weight of about 55 to 60 kilodaltons as determined by non-reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE); and
- d) is a dimer of two peptide chains exhibiting molecular weights of about 27 kilodaltons and 29 kilodaltons, as measured by reducing SDS-PAGE.

79. (New) The hybridoma of Claim 78, wherein said hybridoma produces a monoclonal antibody that recognizes the human 8F4 polypeptide of about 55 kilodaltons to 60 kilodaltons, as determined by non-reducing SDS-PAGE.

80. (New) The hybridoma of Claim 78, wherein said hybridoma produces a monoclonal antibody that recognizes the peptide chain of about 27 kilodaltons, as determined by reducing SDS-PAGE.

81. (New) The hybridoma of Claim 78, wherein said hybridoma produces a monoclonal antibody that recognizes the peptide chain of about 29 kilodaltons, as determined by reducing SDS-PAGE.

82. (New) The hybridoma of Claim 78, wherein said hybridoma produces a monoclonal antibody that recognizes a human 8F4 polypeptide present on activated human CD4⁺ T lymphocytes and activated human CD8⁺ T lymphocytes.

83. (New) The hybridoma of Claim 78, wherein said hybridoma produces a monoclonal antibody that inhibits the biological activity of the human 8F4 polypeptide.

84. (New) The hybridoma of Claim 78, wherein said hybridoma produces a monoclonal antibody that activates the biological activity of the human 8F4 polypeptide.

85. (New) A pharmaceutical composition comprising a monoclonal antibody that recognizes a human 8F4 polypeptide or a fragment thereof, wherein said 8F4 polypeptide:

- a) is an inducible T cell costimulatory molecule;
- b) occurs on two-signal-activated human T lymphocytes;
- c) exhibits a molecular weight of about 55 to 60 kilodaltons as determined by non-reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE); and
- d) is a dimer of two peptide chains exhibiting molecular weights of about 27 kilodaltons and 29 kilodaltons, as measured by reducing SDS-PAGE.

86. (New) The pharmaceutical composition of Claim 85 wherein the monoclonal antibody inhibits the biological activity of the human 8F4 polypeptide.

87. (New) The pharmaceutical composition of Claim 85 wherein the monoclonal antibody activates the biological activity of the human 8F4 polypeptide.

88. (New) A method for producing the monoclonal antibody of Claim 71, comprising: culturing an antibody-secreting hybridoma obtained by fusion of a myeloma cell line cell with a spleen cell of a mouse immunized with 2-signal-activated human T lymphocytes, such that the monoclonal antibody is produced.